Xaliproden lessens oxaliplatin-mediated neuropathy. [Lancet Oncol. 2006] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Lancet Oncol. 2006 Apr;7(4):288.Links

Xaliproden lessens oxaliplatin-mediated neuropathy.

PMID: 16598880 [PubMed - indexed for MEDLINE]

Related articles

Peripheral neuropathy induced by oxaliplatin-based chemotherapy.
J Support Oncol. 2006 Feb; 4(2):82-3.

[J Support Oncol. 2006]
Peripheral sensory neuropathy--fighting cold with cold.
Lancet Oncol. 2008 May; 9(5):415-6.

[Lancet Oncol. 2008]
Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
Ann Oncol. 2001 Mar; 12(3):421-2.

[Ann Oncol. 2001]
ReviewOxaliplatin-safety profile: neurotoxicity.
Semin Oncol. 2003 Aug; 30(4 Suppl 15):5-13.

[Semin Oncol. 2003]
ReviewAn overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
Int J Palliat Nurs. 2001 Jul; 7(7):354-9.

[Int J Palliat Nurs. 2001]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Xaliproden lessens oxaliplatin-mediated neuropathy.Xaliproden lessens oxaliplatin-mediated neuropathy.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show